

# Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Symptomatic COVID-19

JAMA Internal Medicine

182, 42

DOI: [10.1001/jamainternmed.2021.6759](https://doi.org/10.1001/jamainternmed.2021.6759)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ann Robinson's research reviews 3 December 2021. BMJ, The, 2021, 375, n3006.	6.0	0
2	Outpatient Therapies for COVID-19: How Do We Choose?. Open Forum Infectious Diseases, 2022, 9, ofac008.	0.9	18
3	Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis. European Respiratory Journal, 2022, 59, 2102921.	6.7	11
4	Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. European Respiratory Journal, 2022, 59, 2103036.	6.7	9
5	The Use of Inhaled Glucocorticosteroids (ICS) during the COVID-19 Pandemic. Tuberculosis and Lung Diseases, 2022, 100, 7-18.	0.7	0
7	Inhaled Ciclesonide for Patients With Asthma or Chronic Obstructive Pulmonary Disease and COVID-19—Reply. JAMA Internal Medicine, 2022, , .	5.1	0
8	Inhaled Ciclesonide for Patients With Asthma or Chronic Obstructive Pulmonary Disease and COVID-19. JAMA Internal Medicine, 2022, , .	5.1	0
9	Inhaled corticosteroids for the treatment of COVID-19. The Cochrane Library, 2022, 2022, CD015125.	2.8	34
10	Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). Clinical Microbiology and Infection, 2022, 28, 1010-1016.	6.0	21
12	Letter to Sarah Basin et Al.. Respiratory Medicine and Research, 2022, 81, 100895.	0.6	0
13	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. American Journal of Emergency Medicine, 2022, 56, 158-170.	1.6	13
14	Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. Archivos De Bronconeumologia, 2022, 58, 39-50.	0.8	26
15	Do Corticosteroids Reduce Mortality or Progression to Severe Disease for Non-Oxygen Requiring Patients Infected With COVID-19?. Annals of Emergency Medicine, 2022, , .	0.6	1
16	Recommendations for the outpatient drug treatment of patients with COVID-19. Deutsches A&#x0308;rztblatt International, 2022, , .	0.9	2
17	A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study. ERJ Open Research, 2022, 8, 00129-2022.	2.6	9
19	Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary sequelae after COVID-19 Infection. Pharmaceutics, 2022, 14, 1135.	4.5	15
20	An Approach to the Treatment of Children With COVID-19. Pediatric Infectious Disease Journal, 2022, 41, 654-662.	2.0	5
21	Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial. EClinicalMedicine, 2022, 49, 101484.	7.1	9

#	ARTICLE	IF	CITATIONS
22	The effect of inhaled corticosteroids on the outcomes of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 593-600.	3.1	8
24	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	3.7	46
25	Coagulopathy in COVID-19 and anticoagulation clinical trials. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101377.	1.7	3
26	Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. <i>Lancet Infectious Diseases</i> , The, 2023, 23, e22-e33.	9.1	38
27	European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1578-1590.	6.0	9
28	Intranasal Corticosteroid Treatment on Recovery of Long-Term Olfactory Dysfunction Due to COVID-19. <i>Laryngoscope</i> , 2022, 132, 2209-2216.	2.0	11
29	Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19. <i>Microorganisms</i> , 2022, 10, 1639.	3.6	5
30	Inhaled ciclesonide for outpatients with COVID-19: A meta-analysis. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 1129-1130.	3.1	3
31	Effect of corticosteroid therapy on mortality in COVID-19 patients: A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2022, 32, .	8.3	13
32	Outpatient Management of COVID-19: A Primer for the Dermatologist. <i>Current Dermatology Reports</i> , 2022, 11, 318-327.	2.1	1
33	Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	2.0	1
34	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 0, , .	5.8	82
35	Frequent occurrence of mutations in nsp3 and nsp4 of SARS-CoV-2, presumably caused by the inhaled asthma drug ciclesonide. , 0, , .		0
36	Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce. <i>Medical Journal of Australia</i> , 2022, 217, 368-378.	1.7	8
37	Impact of inhaled ciclesonide on asymptomatic or mild COVID-19: A randomized trial. <i>Drug Discoveries and Therapeutics</i> , 2022, 16, 225-232.	1.5	7
38	Pulmonary Sequelae of COVID-19. , 2022, , 13-24.		0
39	Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. <i>Molecular Aspects of Medicine</i> , 2023, 91, 101151.	6.4	16
40	Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 6138.	2.4	5

#	ARTICLE	IF	CITATIONS
41	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. <i>Life</i> , 2022, 12, 1758.	2.4	9
42	Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
43	Inhaled corticosteroids for the treatment of COVID-19. <i>European Respiratory Review</i> , 2022, 31, 220099.	7.1	7
44	COVID-19 in patients with chronic lung disease. <i>Clinics in Chest Medicine</i> , 2022, , .	2.1	1
45	Formulation, Device, and Clinical Factors Influencing the Targeted Delivery of COVID-19 Vaccines to the Lungs. <i>AAPS PharmSciTech</i> , 2023, 24, .	3.3	2
46	Immunomodulatory agents for COVID-19 pneumonia. <i>Clinics in Chest Medicine</i> , 2022, , .	2.1	1
47	Small molecules in the treatment of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	42
48	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118.	2.8	2
49	Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. , 2023, , 99-139.		1
50	Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. <i>JAMA Network Open</i> , 2023, 6, e2253301.	5.9	0
51	Safety and efficacy of glucocorticoids in the treatment of COVID-19: A meta-analysis of randomized control trials. <i>Expert Review of Respiratory Medicine</i> , 2023, 17, 81-96.	2.5	4
52	The development of COVID-19 treatment. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	59
53	Dry powder formulation of azithromycin for COVID-19 therapeutics. <i>Journal of Microencapsulation</i> , 2023, 40, 217-232.	2.8	0
54	Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19). <i>BMJ Open</i> , 2023, 13, e064374.	1.9	5
55	Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?. <i>Inflammopharmacology</i> , 2023, 31, 633-651.	3.9	9
56	Corticosteroids for non-severe COVID-19 infections? Too early to conclude. <i>Korean Journal of Internal Medicine</i> , 2023, 38, 144-146.	1.7	1
58	Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2023, 77, 186-193.	5.8	1
59	Meta-Analysis of Glucocorticoids for Covid-19 Patients Not Receiving Oxygen. , 2023, 2, .		7

#	ARTICLE	IF	CITATIONS
60	Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475.	46.4	112
61	COVID-19 and immunity. , 2023, , 3-32.		0
62	Glucocorticoids in the combination therapy of COVID-19. <i>Meditinskiy Sovet</i> , 2023, , 52-56.	0.5	0
63	Therapeutic Potentials and Candidates for COVID-19. , 2023, 47, 1283-1297.		0
64	Regular Inhaled Corticosteroids Use May Protect Against Severe COVID-19 Outcome in COPD. <i>International Journal of COPD</i> , 0, Volume 18, 1701-1712.	2.3	1
65	Corticosteroids in COVID-19: pros and cons. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	2
66	Inhaled corticosteroid for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 921-930.	3.1	0
67	Inhaled corticosteroidsâ€™ effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. <i>Canadian Journal of Respiratory Therapy</i> , 0, 59, .	0.8	0
68	Chinese herbal medicine Shufeng Jiedu Capsule for patients with mild to moderate coronavirus disease 2019 (COVID-19): Protocol for a randomized, blinded, placebo control trial. <i>European Journal of Integrative Medicine</i> , 2023, 62, 102286.	1.7	0
69	Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19. <i>New England Journal of Medicine</i> , 2023, 389, 1085-1095.	27.0	6
70	From Emergence to Endemicity: A Comprehensive Review of COVID-19. <i>Cureus</i> , 2023, , .	0.5	1
71	Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial. <i>Drug Discoveries and Therapeutics</i> , 2023, 17, 304-311.	1.5	0
72	Effect of Inhaled Ciclesonide in Nonâ€“Critically Ill Hospitalized Patients With Coronavirus Disease 2019: A Multicenter Observational Study in Japan. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.9	0
73	Clinical efficacy of inhaled corticosteroids in patients with coronavirus disease 2019: A living review and meta-analysis. <i>PLoS ONE</i> , 2023, 18, e0294872.	2.5	0
74	Inhaled beclomethasone in the treatment of early COVID-19: a double-blind, placebo-controlled, randomised, hospital-based trial in Sri Lanka. <i>BMJ Open</i> , 2023, 13, e075803.	1.9	0
75	Outpatient randomized controlled trials to reduce COVIDâ€™19 hospitalization: Systematic review and metaâ€“analysis. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	1
76	The Therapy of SARS-CoV-2 Infection in Children. <i>Journal of Clinical Medicine</i> , 2024, 13, 120.	2.4	0
77	Investigational pharmacological agents for the treatment of ARDS. <i>Expert Opinion on Investigational Drugs</i> , 2024, 33, 243-277.	4.1	0

#	ARTICLE	IF	CITATIONS
78	Involvement of Fgf2-mediated tau protein phosphorylation in cognitive deficits induced by sevoflurane in aged rats. <i>Molecular Medicine</i> , 2024, 30, .	4.4	0